Muscular fatigue may result from HIV infection, and may be associated with antiretroviral drug treatment. Clinical features linked to muscle biopsy findings may assist in determining etiology, and guide treatment decisions. This case series examined HIV patients in an ambulatory HIV clinic who received antiretroviral therapy, and complained of unexplained muscular fatigue. Clinical features with measurement of acid-base status, levels of lactate, aminotransferases, triglycerides and creatine kinase were correlated to light and electron microscopic results of muscle biopsy.
Introduction
Muscle fatigue in the HIV-infected patient, defined in this case series as diminished exercise tolerance and subjective muscle fatigue, may result from diverse etiologies that often present with a similar clinical picture.
Overt physical evidence of myopathy may come late in the disease process. The ability to correlate unique and early biochemical findings to specific histopathologic results on muscle biopsy may shed light on the physiologic basis of observed laboratory abnormalities preceding overt myopathy. Despite advances in HIV management, muscle fatigue still often occurs as a result of inflammatory responses to HIV itself, or as a consequence of antiretroviral therapy. 1 Nucleoside analogs inhibit mitochondrial DNA polymerase-γ, leading to disruption of oxidative metabolism. 2 A mitochondrial myopathy, initially noticed with zidovudine in the late 1980s, was attributed to reductions in mitochondrial DNA. 3 Recently, other nucleoside agents have been implicated in producing mitochondrial dysfunction, characterized by a more systemic syndrome of lactic acidosis, lipid alterations, and metabolic disruption of active organs, resulting in pancreatitis and hepatic steatosis. 4, 5 Little is known about the correlation of clinical findings to specific muscle biopsy findings. Knowledge of early changes in clinical and biochemical parameters in relationship to pathologic findings is necessary. Potential interventions in HIV-associated muscle fatigue may vary from discontinuation of antiretroviral therapy in the setting of mitochondrial toxicity, to treatment intensification and use of adjunct anti-inflammatory therapy for patients manifesting HIV-associated polymyositis. 6, 7 screen for common etiologies of fatigue in the clinic population. This included a complete blood cell count to exclude anemia; serologic screening to rule out recent acquisition of viral hepatitis of types A, B and C; a total testosterone level to assess gonadal function; and a thyroid profile consisting of a thyroid-stimulating hormone and free thyroxine levels.
Patients who complained of muscle fatigue without discernible cause by history, physical exam, and screening laboratory evaluation underwent further laboratory testing which measured acid-base status (room air arterial blood gases, and venous plasma lactate), and fasting triglycerides, creatine kinase, and aminotransferase levels. All patients underwent hepatic ultrasonography. If the plasma lactate level was elevated, antiretroviral therapy was halted out of a concern for symptomatic hyperlactatemia. Patients were hospitalized for supportive care only if acidosis was significant, or they required intravenous rehydration. No other specific interventions were performed. All patients underwent muscle biopsy of the deltoid within three weeks of their initial presentation. Biopsy specimens were examined using routine light microscopy (LM), histochemistry and electron microscopy (EM) by a neuropathologist (S.N.) at Sutter Medical Center in Sacramento, California.
Results
Four patients met the criteria of unexplained muscle fatigue, and following informed consent, underwent the aforementioned laboratory testing with subsequent muscle biopsy. The patients were male with CD4 lymphocyte counts ranging from 22 to 1,023 µL, and on highly active antiretroviral therapy (HAART) with two nucleoside analogs at the time of their illness. All had received stavudine (d4T) with mean treatment duration of 27 months. Other nucleosides included didanosine (ddI), and lamivudine (3TC). Table 1 gives important immunologic parameters of CD4 cell count and viral load at presentation, and a description of prescribed antiretroviral drugs and duration of therapy. On biopsy, three patients had evidence of an acquired mitochondrial myopathy, and one patient had histologic changes of polymyositis. Table 2 relates key clinical parameters to biopsy findings. Those with acquired mitochondrial myopathy tended to have a systemic clinical syndrome with metabolic changes consisting of low-level lactatemia, a significant rise in triglycerides, and aminotransferase levels. Plasma lactate for this group was high on repeat sampling. Fatty infiltration on liver ultrasound was noted in two of three patients with acquired mitochondrial myopathy. All patients with acquired mitochondrial myopathy noted resolution of symptoms over three to four weeks with discontinuation of antiretroviral therapy. Patient 3 had significant acidosis complicated by diarrhea and bicarbonate loss, and required hospitalization for intravenous fluid administration for two days. Patient 4 with polymyositis had an isolated high creatine kinase level. His plasma lactate was marginally elevated, but was normal upon repeat testing the next day with normal acid base parameters, suggesting the initial increase was possibly a lab error. The patient received electromyography that showed changes classic for polymyositis, and was treated with oral prednisone therapy after a muscle biopsy.
In Figure 1A , the Modified Trichome Stain on the frozen muscle biopsy specimen from Patient 1 shows uniform fibers without individual fiber necrosis, and absence of ragged-red fibers or inflammatory response by light microscopy. However, the electron microscopic picture on the biopsy from this patient shows the prominent increase in number and size of the mitochondira in Figure 1B . There is also close association of these abnormal mitochondria with increased number of lipid droplets. The myofibers are otherwise intact. In contrast, the inflammatory myopathic features seen on the muscle biopsy from Patient 4 are demonstrated in the light microscopic field from the Modified Trichome stained material in Figure 1C . There is wide variation in fiber size associated with individual fiber necrosis, interstitial mononuclear inflammation, and extensive fibrosis. The electron microscopic findings in Figure  1D , in contrast to Patient 1, reveal nonspecific changes characterized by a uniform number, distribution, and size of muscle mitochondria. 
Discussion
Skeletal muscle involvement occurs in all stages of HIV infection. Muscle weakness associated with overt physical signs may be seen during wasting and cachexia, or accompany systemic opportunistic infections and HIV-related malignancies. 8 Determining the etiology of muscle fatigue, especially when chronic and unexplained by physical exam, remains a challenge. In the physical exam, differentiating an HIV-associated myopathy from an acquired drug-related mitochondrial myopathy is important. The latter, first recognized as a complication of zidovudine therapy, presumably results from the ability of nucleoside analogs to alter mitochondrial function through inhibition of DNA polymerase-γ, and impairment of oxidative phosphorylation. Early reports of mitochondrial myopathy associated with zidovudine usage do not describe a systemic metabolic syndrome. 1, 9 Reasons likely include a prior emphasis on muscle weakness, unawareness of potential biochemical changes due to toxicity of nucleoside analogs, and the unique tissue uptake of zidovudine, favoring its effect in muscle over other metabolically active organs such as the liver. 10 More recently, there is a growing awareness of mitochondrial toxicity as a systemic syndrome, which is a chronic or cumulative toxicity of long-term treatment with drugs such as stavudine and zalcitabine (ddC) that inhibit DNA polymerase-γ to a greater degree. 11 Case series of symptomatic lactic acidosis have shown consistent lipid abnormalities in association with hepatic steatosis, and occasionally pancreatitis. The latter syndrome has been associated primarily with stavudine, and discontinuation of the drug has coincided with a resolution of symptoms and acidosis. 12 All our patients with acquired mitohondrial myopathy had received stavudine for a considerable time, and had demonstrated abrupt increases in their fasting triglyceride levels. This has been attributed to impairment of beta-oxidation of fatty acids associated with mitochondrial dysfunction. 13 It is unclear whether the steatosis suggested by hepatic ultrasonography results from deposition of fat within the liver, or from primary hepatocellular dysfunction. The proclivity towards a more systemic syndrome seen with stavudine, as opposed to zidovudine's primary muscle effect, may result from differences in each drug's affinity for forms of thymidine kinase. Thymidine kinase phosphorylates thymidine nucleoside analogs, and has tissue specific forms and a distribution that may account for the specific organ toxicities of nucleoside analogs. 14, 15 The physical appearance of patients with mitochondrial toxicity was unremarkable in these cases. All had preserved muscle mass without deficits in strength, and fatigability was not demonstrable upon physical examination despite complaints of diminished exercise tolerance. Waiting for clear-cut physical evidence of myopathy would have not been in the best interest of these patients who were all systemically ill. Those with acquired mitochondrial disease showed a low CO 2 with moderate anion gap elevation, suggesting chronic respiratory compensation for a low-level systemic acidosis. In contrast, the sole patient with polymyositis had only a high creatine kinase level. Physical examination showed no focal deficit in strength, but lean body cell mass was below normal with less than 35 percent, compatible with his biopsy findings of severe fibrosis replacing muscle fibers. Overall, Patient 4 presented with a nonsystemic picture, pointing towards specific muscle disease based upon his high creatine kinase level and loss of muscle mass.
Conclusion
Acquired mitochondrial disease may manifest systemically in the setting of antiretroviral therapy. Patients without metabolic changes, but demonstrating evidence of primary muscle weakness or wasting, should be screened with a serum creatine kinase level. An elevated level may lead to a consideration of an electromyography Figure 1A , but numerous and enlarged mitochondria with associated lipid droplets in Figure 1B . Figure 1C, and EM (x3000) shows nonspecific myofiber degeneration, but normal mitochondria in Figure 1D .
Photos courtesy of Surl Nielsen (EMG). Accompanying biochemical derangements of mitochondrial toxicity may herald overt muscle disease, and physical signs of weakness may not be present. Useful tests for detecting this syndrome are fasting triglyceride and aminotransferase levels, both of which may abruptly increase during prodromal stages. Ultrasonography of the liver that demonstrates steatosis may also serve as a noninvasive marker of mitochondrial dysfunction.
When mitochondrial dysfunction is present in the setting of chronic nucleoside analog therapy, physicians need to make a choice about continuing these drugs. Physicians can choose to substitute tenofovir for stavudine. Recent data from in vitro cell culture model suggests that tenofovir does not deplete mitochondrial DNA, and has no significant effect in inhibition of DNA polymerase-γ. 16 Surveillance studies are needed to confirm relative safety, but currently tenofovir appears to offer a treatment alternative in the presence of mitochondrial toxicity. For physicians who choose to discontinue nucleoside analogs, dual protease inhibitors using pharmacokinetic enhancement may provide control of viremia. Ritonavir/saquinavir given alone twice daily demonstrate comparable results with the same regimen intensified with nucleoside analogs, suggesting dual protease inhibitor combinations can achieve control of viremia without need for nucleoside combinations for some patients. 17, 18 For patients with insufficient anti-HIV activity on only protease inhibitors, addition of a non-nucleoside drug such as efavirenz or neverapine may also be carefully considered, provided attention is given to complex drug interactions.
Recognition and management of long-term drug toxicities of anti-HIV therapies is a necessary consequence of the successes of medical treatment of HIV disease. ■
